Analysts expect that Myomo, Inc. (NASDAQ:MYO) will announce ($0.15) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Myomo’s earnings, with estimates ranging from ($0.17) to ($0.13). Myomo posted earnings per share of ($0.21) in the same quarter last year, which would suggest a positive year-over-year growth rate of 28.6%. The business is expected to report its next earnings results on Monday, November 4th.

According to Zacks, analysts expect that Myomo will report full year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.68) to ($0.58). For the next year, analysts forecast that the company will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.59) to ($0.35). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow Myomo.

Myomo (NASDAQ:MYO) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.02. The business had revenue of $0.88 million during the quarter, compared to the consensus estimate of $1.09 million.

NASDAQ:MYO traded down $0.04 during trading hours on Friday, reaching $0.67. The company’s stock had a trading volume of 38,300 shares, compared to its average volume of 79,779. Myomo has a 12 month low of $0.66 and a 12 month high of $2.69. The stock has a 50 day moving average price of $0.76 and a two-hundred day moving average price of $1.05.

About Myomo

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

Further Reading: How Do Front-End Loads Impact an Investment?

Get a free copy of the Zacks research report on Myomo (MYO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.